All Pathways
Infectious DiseaseManagement

Candidemia & Invasive Candidiasis Management (IDSA 2016)

Candidemia & Invasive Candidiasis Management (IDSA 2016): Candidemia Diagnosed → Initial Management → Empiric Antifungal Therapy → Candida Species Ident...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Candidemia Diagnosed

    Blood culture positive for Candida species

    1. Action

      Initial Management

      Start antifungal immediately

      • Remove all central venous catheters
      • Repeat blood cultures daily until negative
      • Dilated ophthalmologic exam
      • Echo if prolonged candidemia or valve disease
      1. Action

        Empiric Antifungal Therapy

        Echinocandin first-line

        • Caspofungin 70mg load, then 50mg daily, OR
        • Micafungin 100mg daily, OR
        • Anidulafungin 200mg load, then 100mg daily
        • Fluconazole alternative if low resistance risk
        1. Decision

          Candida Species Identification

          Critical for de-escalation

          1. Action

            C. albicans (Most Common)

            Usually fluconazole-susceptible

            • If stable and susceptible: Can de-escalate to Fluconazole 400mg daily
            • Continue echinocandin if critically ill
            1. Action

              Source Control

              Essential for cure

              • Remove all CVCs - do NOT attempt salvage
              • Drain abscesses
              • Evaluate for deep-seated infection: Eye, heart, kidney, liver, spleen
              1. Action

                Ophthalmologic Exam

                Within first week

                • Chorioretinitis in 5-15%
                • If positive: Intravitreal antifungal + systemic
                • Longer duration of therapy needed
                1. Action

                  Duration of Therapy

                  14 days minimum from negative culture

                  • Uncomplicated: 14 days from first negative culture
                  • Endocarditis: 6 weeks after valve surgery
                  • Eye involvement: 4-6 weeks
                  • Deep-seated: Individualized
                  1. Outcome

                    Resolved

                    Negative cultures, completed therapy

                  2. Warning

                    Complications

                    Endophthalmitis, endocarditis, metastatic

              2. Action

                Echocardiogram

                If risk factors

                • Persistent candidemia >72h
                • Prior valve disease, prosthetic valve
                • IVDU
                • TTE first; TEE if high suspicion
          2. Action

            C. glabrata

            Often fluconazole-resistant

            • Continue echinocandin
            • Await susceptibilities before considering azole
            • High-dose fluconazole 800mg if susceptible
          3. Action

            C. krusei

            Intrinsically fluconazole-resistant

            • Continue echinocandin
            • Voriconazole alternative if needed
          4. Warning

            C. auris

            Multi-drug resistant, infection control alert

            • Often resistant to fluconazole and echinocandins
            • Use echinocandin initially; await susceptibilities
            • Amphotericin B if echinocandin-resistant
            • Contact precautions, notify infection control

Guideline Source

IDSA Clinical Practice Guidelines for the Management of Candidiasis 2016

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • ⚠️ UNVALIDATED DRAFT: This algorithm was AI-generated from guideline summaries and has NOT been reviewed by clinical experts. All doses, thresholds, and pathways MUST be verified against primary sources by qualified clinicians before clinical use. Do not use for patient care without expert validation.
  • Species identification critical for therapy
  • Echinocandin resistance emerging
  • Line removal essential
  • Eye exam mandatory

Applicable Regions

USEU
Version 1Next review: 2027-01-11

Frequently Asked Questions

What is the Candidemia & Invasive Candidiasis Management (IDSA 2016)?

The Candidemia & Invasive Candidiasis Management (IDSA 2016) is a management clinical algorithm for Infectious Disease. It provides a structured decision tree to guide clinical decision-making, based on IDSA Clinical Practice Guidelines for the Management of Candidiasis 2016.

What guideline is the Candidemia & Invasive Candidiasis Management (IDSA 2016) based on?

This algorithm is based on IDSA Clinical Practice Guidelines for the Management of Candidiasis 2016 (DOI: 10.1093/cid/civ933).

What are the limitations of the Candidemia & Invasive Candidiasis Management (IDSA 2016)?

Known limitations include: ⚠️ UNVALIDATED DRAFT: This algorithm was AI-generated from guideline summaries and has NOT been reviewed by clinical experts. All doses, thresholds, and pathways MUST be verified against primary sources by qualified clinicians before clinical use. Do not use for patient care without expert validation.; Species identification critical for therapy; Echinocandin resistance emerging; Line removal essential; Eye exam mandatory. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Candidemia & Invasive Candidiasis Management (IDSA 2016) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free